Larraufie, Marie-Helene et al. published their research in Bioorganic & Medicinal Chemistry Letters in 2015 |CAS: 1019442-22-8

The Article related to ketone preparation pharmacokinetics, covalent, erastin, ferroptosis, metabolic stability, reactive carbonyl, Pharmacology: Structure-Activity and other aspects.Application In Synthesis of 5-Bromo-2-isopropoxyaniline

On November 1, 2015, Larraufie, Marie-Helene; Yang, Wan Seok; Jiang, Elise; Thomas, Ajit G.; Slusher, Barbara S.; Stockwell, Brent R. published an article.Application In Synthesis of 5-Bromo-2-isopropoxyaniline The title of the article was Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility. And the article contained the following:

Introducing a reactive carbonyl to a scaffold that does not otherwise have an electrophilic functionality to create a reversible covalent inhibitor is a potentially useful strategy for enhancing compound potency. However, aldehydes are metabolically unstable, which precludes the use of this strategy for compounds to be tested in animal models or in human clin. studies. To overcome this limitation, the authors designed ketone-based functionalities capable of forming reversible covalent adducts, while displaying high metabolic stability, and imparting improved water solubility to their pendant scaffold. The authors tested this strategy on the ferroptosis inducer and exptl. therapeutic erastin, and observed substantial increases in compound potency. In particular, a new carbonyl erastin analog, termed IKE, displayed improved potency, solubility and metabolic stability, thus representing an ideal candidate for future in vivo cancer therapeutic applications. The experimental process involved the reaction of 5-Bromo-2-isopropoxyaniline(cas: 1019442-22-8).Application In Synthesis of 5-Bromo-2-isopropoxyaniline

The Article related to ketone preparation pharmacokinetics, covalent, erastin, ferroptosis, metabolic stability, reactive carbonyl, Pharmacology: Structure-Activity and other aspects.Application In Synthesis of 5-Bromo-2-isopropoxyaniline

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Stockwell, Brent R. et al. published their patent in 2015 |CAS: 1019442-22-8

The Article related to antitumor quinazolinone preparation oncogenic ras mutation cancer therapy, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application In Synthesis of 5-Bromo-2-isopropoxyaniline

On June 25, 2015, Stockwell, Brent R.; Welsch, Matthew; Yang, Wan Seok published a patent.Application In Synthesis of 5-Bromo-2-isopropoxyaniline The title of the patent was Quinazolinone-based oncogenic-ras-selective lethal compounds and their use. And the patent contained the following:

The present invention provides, inter alia, compounds having the structure (1) compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided. The experimental process involved the reaction of 5-Bromo-2-isopropoxyaniline(cas: 1019442-22-8).Application In Synthesis of 5-Bromo-2-isopropoxyaniline

The Article related to antitumor quinazolinone preparation oncogenic ras mutation cancer therapy, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application In Synthesis of 5-Bromo-2-isopropoxyaniline

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Stockwell, Brent R. et al. published their patent in 2014 |CAS: 1019442-22-8

The Article related to antitumor quinazolinone preparation oncogenic ras mutation cancer therapy, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.HPLC of Formula: 1019442-22-8

On January 16, 2014, Stockwell, Brent R.; Welsch, Matthew; Yang, Wan Seok published a patent.HPLC of Formula: 1019442-22-8 The title of the patent was Quinazolinone-based oncogenic-ras-selective lethal compounds and their use. And the patent contained the following:

The present invention provides compounds for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided. The experimental process involved the reaction of 5-Bromo-2-isopropoxyaniline(cas: 1019442-22-8).HPLC of Formula: 1019442-22-8

The Article related to antitumor quinazolinone preparation oncogenic ras mutation cancer therapy, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.HPLC of Formula: 1019442-22-8

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary